Alliance Pharma Share Discussion Threads

[2vdm] 29/1/2020 14:58

This was a post last year in Investors Chronicle:

"The only cloud comes from a Competition and Markets Authority (CMA) investigation into the price of one of the medicines Alliance licenses to another company. Alliance denies that it has any involvement in the pricing of prochlorperazine, which generated less than £0.2m of revenue in 2018, so this case shouldn’t cause investors to lose too much sleep. But a clampdown by the CMA on drug price inflation is not good news"

Given that APH's turnover is circa £118 million, it's hardly a major issue, although I understand winning's comment above. My view as a LTH is that if the price takes a hit in the event that the CMA rules against it and institutions dump stock, then it will be a wonderful buying opportunity for the long term. Just my view.

[2vdm] 23/1/2020 19:06

Thanks Mazarin

[winnings1] 22/1/2020 09:39

If the 'price fixing' enquiry were out of the way, the share price would have risen
a bit further. I am sitting on my hands waiting for the result of the enquiry.

[mazarin] 22/1/2020 09:20

The ‘flip side’ is that any hint of bad news and APH plummets like a stone before you can do anything about it. I think it’s the rather unusual profile of the major APH investors. A lot are held by Institutions and family connected Investors. Institutions take time to analyse results before adding, but will ‘drop’ instantly whenever there’s any possible hint of trouble. Regardless of whether the rumour is justified or within ‘the gift’ of the company. I’ve experienced many of examples during my years of holding, the Sanofi Pasteur flood disaster years ago and more recently the ‘price fixing’ enquiry, each took it’s toll on the share price that takes a long time to recover.

[2vdm] 22/1/2020 09:05

Well I bought another 8K this am first thing and might get some more. All bottom drawer investment for me so can take the long view

[mazarin] 22/1/2020 08:59

It’s always been the case with APH, even when the news is good. They report increased profit, cash generative growth and the ability to reduce debt. All these are solid factors expected of good management, but the share price hardly moves. However I fully expect it to improve when the news is digested. It’s just slow to respond for some reason.

[2vdm] 22/1/2020 08:14

Bit surprised the share price hasn't moved yet. Not a stock that will set the world on fire, but with a well managed board, increased profits across all ranges, cash generative and paying down its debt substantially. Great set of results imo.

[winnings1] 22/1/2020 08:09

Still no word about the investigation into the sale of a licence to a product which resulted in anti-competetive pricing of that product.

[mazarin] 31/12/2019 10:33

Mark, as one who has been in and out of APH over last 10 years. I understand your sentiment and rationale. Time will tell if its well founded, however when I'm out, I find myself looking to get back in and in the process, have missed a few significant rises. Thanks for sharing.

[marksp2011] 30/12/2019 17:26

I am out.

If the CEO and CFO don't see the case to hold their shares, why should I?

[winnings1] 30/12/2019 08:30

Share price looks high considering there is still no certainty in respect of the outcome of the investigation into possible breach of competition rules.

[marksp2011] 29/12/2019 18:45

If the leadership is selling and a major shareholder reducing what is the investment case?

Trailing PE=23 and earnings yield of 4.4%

I am talking myself into selling.

[winnings1] 27/12/2019 16:44

We are still awaiting the outcome of the investigation into a suspected breach of competition rules in respect of the sale of one of APH's medicines to a pharma company who multiplied the price of that medicine. Should we not have heard by now, one way or another?

[marksp2011] 27/12/2019 13:20

It has been rising for 4 months
The fall was overdone IMHO

[saeed45] 27/12/2019 11:19

Why the sudden surge in price guys? Is this a good time to buy?

[marksp2011] 24/12/2019 12:16

I see another insider has dumped a bucket load of stock and the biggest shareholder has also reduced.

That isn't good news.

[marksp2011] 23/12/2019 11:44

For a Christmas bonus have a look at PZC, Nick Train announced a small holding, tiny really on the scale of things and it has been motoring ever since

[dround87] 23/12/2019 08:21

Christmas bonus! Still out but good to see this now edging up. Well done everyone.

[montynj] 20/12/2019 15:01

Positive chart breakout today from a consolidation pattern

[sunningdale1] 16/12/2019 10:58

Following on from my previous Open Orphans (ORPH) post, Cathal Friel has delivered as promised with the all share merger with hVIVO (HVO). Seeing as HVO was trading at 30p at the start of the year, 2.47 ORPH shares for for each HVO share at 15.6p is great value. This follows partnerships with biopharma giant Ipsen Group and Venn’s deal with Carna Bioscience, and will leverage up and commercialise HVO’s sb through the Open Orphan health data platform.

At 5.6p this still values ORPH at just £14m - combine in HVO at £11m plus the preferred partnership agreements and ORPH is set for a big 2020

[cumnor] 27/11/2019 09:23

Of little or no relevance to company earnings-wasn't selling for several reasons so good to see decisive action by mgmt to allocate marketing monies elsewhere or take on another product from elsewhere.

[marksp2011] 27/11/2019 08:55

maz

To some extent, the price move isn't really the issue. What makes me angry is the lack of clarity in the announcements. I rewrote an RNS for another AIM company and asked them if that was what they really meant. The news itself wasn't good but was transient so represented a buying opportunity. By the time they had finished spinning it it was impossible to understand and as a result the share price dropped like a brick.

These are supposed to be communications not advertorials.

[mazarin] 27/11/2019 08:14

You may well have a point as it was marked lower on opening